CTI BioPharma announces extension of FDA review period for pacritinib in myelofibrosis with severe thrombocytopenia.
The prescription drug user fee act (pdufa) action date has been extended by three months to february 28, 2022.
In the second quarter of 2021, the FDA granted priority review for CTI's NDA for patients with myelofibrosis with a PDUFA date of November 30, 2021. In the course of product labeling discussions, the FDA requested additional clinical data, which was submitted to the agency on November 24, 2021. Earlier today, the FDA informed the Company that it considers the data submission to constitute a "major amendment" to the NDA and therefore the PDUFA date has been extended by three months to provide additional time for a full review of the submission. At the current time, CTI is not aware of any major deficiencies in the application.
Related news and insights
Eisai and Merck Inc., announced the publication of results from the Phase III Study 309/KEYNOTE-775 trial in the January 19, 2022 edition of the New England Journal of Medicine.
Omeros Corporation confirmed that earlier this month the company submitted to the FDA its response to the Agency’s Complete Response Letter (CRL) for narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA).
Sorrento Therapeutics, Inc. announced the release of new data on the Omicron variant neutralizing antibody (nAb) STI 9167, COVISHIELD, an advanced stage antibody discovered and developed for clinical trials in an ongoing collaboration between immunologists and virologists at Sorrento and the Icahn School of Medicine at Mount Sinai in New York, NY.